Jazz Pharmaceuticals plc JAZZ
today announced that the first patient has been enrolled and dosed in a
clinical trial of Erwinaze^® (asparaginase Erwinia chrysanthemi) administered
intravenously (IV) as an alternative method of administration to treat
patients with acute lymphoblastic leukemia (ALL) with hypersensitivity to E.
coli-derived asparaginase therapy.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in